Efpegsomatropin

Drug Profile

Efpegsomatropin

Alternative Names: HM-10560A; LAPS-hGH; LAPS-rhGH; Long acting somatropin - Hanmi Pharmaceutical

Latest Information Update: 24 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Growth hormones; Hormonal replacements; Polyethylene glycols
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Somatotropin deficiency

Most Recent Events

  • 13 Mar 2015 Phase-II clinical trials in Somatotropin deficiency in Ukraine, Serbia, Russia, Romania, India, Bulgaria and South Korea (SC) after October 2011 (EudraCT2011-001826-61)
  • 06 Feb 2014 Hanmi Pharmaceutical completes enrolment in its phase II trial for Somatotropin deficiency in Hungary (NCT01822340)
  • 13 Dec 2012 Phase II development is ongoing in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top